Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms SCALP
- Sponsors Novartis Pharmaceuticals
- 16 Feb 2018 Results published in the Novartis Media Release.
- 16 Feb 2018 According to a Novartis media release, data from this study were presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting.
- 08 Feb 2018 According to a Novartis media release, US Food and Drug Administration (FDA) has approved Cosentyx label update to include moderate-to-severe scalp psoriasis based on the data from this study.